These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1823 related articles for article (PubMed ID: 33958324)

  • 1. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
    Simon D; Tascilar K; Fagni F; Krönke G; Kleyer A; Meder C; Atreya R; Leppkes M; Kremer AE; Ramming A; Pachowsky ML; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Berking C; Sticherling M; Neurath MF; Schett G
    Ann Rheum Dis; 2021 Oct; 80(10):1312-1316. PubMed ID: 33958324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
    Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
    Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
    [No Abstract]   [Full Text] [Related]  

  • 4. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
    Geisen UM; Berner DK; Tran F; Sümbül M; Vullriede L; Ciripoi M; Reid HM; Schaffarzyk A; Longardt AC; Franzenburg J; Hoff P; Schirmer JH; Zeuner R; Friedrichs A; Steinbach A; Knies C; Markewitz RD; Morrison PJ; Gerdes S; Schreiber S; Hoyer BF
    Ann Rheum Dis; 2021 Oct; 80(10):1306-1311. PubMed ID: 33762264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
    Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
    Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
    Spiera R; Jinich S; Jannat-Khah D
    Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters.
    Magliulo D; Wade SD; Kyttaris VC
    Clin Immunol; 2022 Jan; 234():108897. PubMed ID: 34848357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
    Ruddy JA; Connolly CM; Boyarsky BJ; Werbel WA; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
    Ann Rheum Dis; 2021 Oct; 80(10):1351-1352. PubMed ID: 34031032
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
    Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
    Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
    Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
    Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
    Prendecki M; Clarke C; Edwards H; McIntyre S; Mortimer P; Gleeson S; Martin P; Thomson T; Randell P; Shah A; Singanayagam A; Lightstone L; Cox A; Kelleher P; Willicombe M; McAdoo SP
    Ann Rheum Dis; 2021 Oct; 80(10):1322-1329. PubMed ID: 34362747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
    Albach FN; Burmester GR; Biesen R
    Ann Rheum Dis; 2021 Oct; 80(10):1361-1362. PubMed ID: 34167947
    [No Abstract]   [Full Text] [Related]  

  • 17. Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.
    Golding B; Lee Y; Golding H; Khurana S
    Ann Rheum Dis; 2021 Oct; 80(10):1359-1361. PubMed ID: 34272252
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort.
    Simon D; Tascilar K; Kleyer A; Fagni F; Krönke G; Meder C; Dietrich P; Orlemann T; Kliem T; Mößner J; Liphardt AM; Schönau V; Bohr D; Schuster L; Hartmann F; Leppkes M; Ramming A; Pachowsky M; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Atreya R; Berking C; Sticherling M; Neurath MF; Schett G
    Arthritis Rheumatol; 2022 May; 74(5):783-790. PubMed ID: 34951137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
    Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
    BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination.
    Firinu D; Perra A; Campagna M; Littera R; Fenu G; Meloni F; Cipri S; Sedda F; Conti M; Miglianti M; Costanzo G; Secci M; Usai G; Carta MG; Cappai R; Orrù G; Del Giacco S; Coghe F; Chessa L
    Clin Exp Med; 2022 Aug; 22(3):477-485. PubMed ID: 34741188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.